Nasdaq adds Moderna to the Nasdaq-100. Moderna stock gains 2.51 percent

Published on 10/09/2026 at 15:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 145.00 million, up 2.00 percent year over year. Moderna stock costs EUR 179.38 on October 9, 2026 after EUR 174.99.

Key points in brief

Nasdaq announced Moderna would join the Nasdaq-100 before market open on October 9, 2026.
Moderna reported USD 145.00 million of second-quarter 2026 revenue, up 2.00 percent year over year.
The Lang & Schwarz quote was EUR 179.38 on October 9, 2026, up 2.51 percent versus EUR 174.99.
Morgan Stanley raised its target from USD 89.00 to USD 95.00 while keeping an Equal Weight rating.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna (ISIN US60770K1079) was trading at EUR 179.38 at Lang & Schwarz on October 9, 2026 at 3:34 p.m. CEST, up 2.51 percent versus the prior close of EUR 174.99. Nasdaq announced on October 1, 2026 that Moderna would join the Nasdaq-100 before market open on October 9, replacing Warner Bros. Discovery.

Index entry meets weak earnings

The index change arrives against a still loss-making operating profile. In the second quarter of 2026, Moderna generated USD 145.00 million of revenue, up 2.00 percent from the same quarter a year earlier, while its GAAP net loss was USD 782.00 million.

Yahoo Finance reported that the second-quarter loss improved 5.00 percent from the prior-year period, while GAAP loss per share narrowed to USD 1.97 from USD 2.13. Management reiterated its expectation for 2026 revenue growth of up to 10.00 percent.

What does the index entry change?

The Nasdaq-100 is tracked by more than 200 investment products with over USD 800.0 billion in assets under management, according to Nasdaq. That structure makes Moderna's inclusion relevant for passive portfolios, although the company-specific fundamentals remain tied to vaccine demand and clinical development rather than index membership.

Analyst expectations remain divided. MarketBeat reported on October 7, 2026 that Morgan Stanley raised its price target from USD 89.00 to USD 95.00 while retaining an Equal Weight rating. The same report cited a Hold consensus based on seven Buy, 13 Hold and five Sell ratings.

Three milestones frame the move

On August 28, 2026, Moderna announced pricing of a USD 2.6 billion convertible senior notes offering, with proceeds available for oncology investment and debt repayment, according to Moderna. On September 21, 2026, the company said Phase 3 data for intismeran autogene would be presented at the ESMO Congress 2026, also in the company release archive.

On October 1, 2026, Nasdaq said Moderna would enter the Nasdaq-100, an index of 100 large Nasdaq-listed non-financial companies. The current event is therefore a market-structure milestone layered onto a pipeline story that still depends on clinical and commercial execution.

Upcoming investor dates

Moderna plans an investor event by webcast on October 24, 2026, at 1:00 p.m. EDT, according to Moderna. Its second-quarter earnings call also identified an Analyst Day for November 12, 2026, giving investors two dated opportunities to assess the oncology and vaccine pipeline.

Moderna stock trades higher

At 3:34 p.m. CEST on October 9, 2026, Moderna was trading at EUR 179.38 at Lang & Schwarz, up 2.51 percent versus the EUR 174.99 prior close at Lang & Schwarz dated October 8, 2026. On Nasdaq, the finance quote showed USD 207.39 at 9:39 a.m. ET on October 9, 2026, while the same source showed a 52-week range of USD 22.28 to USD 212.22 and a market capitalization of USD 82.3 billion. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.